Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30

$29.86−1.94 (-6.10%)

Close on Nov 12, 2026Market cap $3.33BP/E –Yield –

Amylyx Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Amylyx Pharmaceuticals's EV/EBITDA was 23.3× on Feb 29, 2024.

Period	Period end	Value	Change (pts)
2024	Feb 29, 2024	23.3×	–

Parsed from the XBRL in Amylyx Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AMLX.

Revenue growth-100.0% · median 342.1%

Advertisement
300 × 250

See a number that looks wrong?